Clinical trial
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
NCT04139304
Study timeline
Study start (actual)2021-05-24Date precision: day
Registry last updated2026-06-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Interventions
CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
DaratumumabBIOLOGICAL
DoxorubicinDRUG · verified · RxNorm: doxorubicin
Doxorubicin HydrochlorideDRUG · verified · RxNorm: doxorubicin hydrochloride
EtoposideDRUG · verified · RxNorm: etoposide
PrednisoneDRUG · verified · RxNorm: prednisone
VincristineDRUG · verified · RxNorm: vincristine
Vincristine SulfateDRUG · verified · RxNorm: vincristine sulfate
Sponsors & collaborators
AIDS Malignancy Consortiumlead sponsor
National Cancer Institute (NCI)collaborator
Janssen Scientific Affairs, LLCcollaborator
Montefiore Medical Centercollaborator
Memorial Sloan Kettering Cancer Centercollaborator
AIDS and Cancer Specimen Resourcecollaborator
The Emmes Company, LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04139304 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.